# Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

> **NCT04652206** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Scandion Oncology A/S** · enrollment: 18 (estimated)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Inoperable Disease
- Localized Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** SCO-101
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT04652206
- **Lead sponsor:** Scandion Oncology A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-27
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-05-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2021-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652206, "Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04652206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*